MinorSodium-glucose cotransporter-2 (SGLT2) inhibitor×Gabapentinoids (antiepileptics)
Updated · Methodology
Mechanism
Gabapentin is not metabolised in the body and is excreted unchanged by the kidneys. Its clearance is directly proportional to creatinine clearance (gabapentin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dapagliflozin is metabolised mainly by UGT1A9 to an inactive glucuronide that is excreted in the urine, and it neither inhibits nor induces cytochrome P450 enzymes (dapagliflozin SmPC, European Medicines Agency, EMA). In studies, dapagliflozin did not meaningfully inhibit the transporters P-glycoprotein (P-gp), OCT2, OAT1 and OAT3, and gabapentin did not inhibit the main cytochrome P450 enzymes (Farxiga and Neurontin labels, US Food and Drug Administration, FDA). The metabolic pathways of the two drugs do not overlap, and neither drug's documents name the other drug or its class.
Symptoms
The documents describe no symptoms linked to this combination. Gabapentin very commonly causes somnolence, dizziness and ataxia (gabapentin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dapagliflozin increases urine output and can lower blood pressure slightly. Its common effects include dizziness and genital and urinary tract infections, and a rare serious complication is diabetic ketoacidosis, sometimes with blood glucose below 14 mmol/L (dapagliflozin SmPC, European Medicines Agency, EMA).
Management
According to the documents, the combination is acceptable, and the doses of gabapentin and dapagliflozin need no change. No document names the pair, and their elimination pathways do not overlap (gabapentin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; dapagliflozin SmPC, European Medicines Agency, EMA). The gabapentin dose is based on creatinine clearance and is reduced according to the SmPC table when creatinine clearance is below 79 mL/min (gabapentin SmPC, AEMPS). Before dapagliflozin starts, renal function and volume status are assessed, and volume depletion is corrected first (Farxiga label, US Food and Drug Administration, FDA). In illnesses that can lead to fluid loss, such as gastrointestinal illness, volume status is monitored closely, and if volume depletion develops, dapagliflozin is interrupted until it is corrected (dapagliflozin SmPC, EMA). People are advised not to drive until they know whether gabapentin affects their driving, because it causes somnolence and dizziness (Neurontin label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Neurontin 300 mg cápsulas duras (gabapentina) (2026)– AEMPS, CIMA, nº registro 60621, revisión 01/2026, secciones 4.4 y 4.5
- FDA: Neurontin (gabapentin) – Prescribing Information (2026)– FDA, DailyMed SPL, Viatris Specialty, sections 5.8, 7.1 and 12.3
- EMA: Ficha técnica: Dapagliflozina (EU/1/12/795), sección 4.5 (2026)– EMA, Forxiga 10 mg comprimidos recubiertos con película (AstraZeneca AB, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 112795007, consultada 03.11.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.4, 4.5 y 5.2
- FDA: Farxiga (dapagliflozin) prescribing information (2026)– FDA, DailyMed, AstraZeneca Pharmaceuticals LP, setid 72ad22ae-efe6-4cd6-a302-98aaee423d69, v49, 06/2026, sections 2.1, 5.2, 5.4, 7 (Table 4) and 12.3